This includes ABRYSVO ® (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug Administration approved for the prevention of RSV-associated LRTD in adults aged 18 to ...

the prevention of LRTD caused by RSV in people 18 through 59 years of age who are at increased risk for LRTD caused by RSV pregnant individuals at 32 through 36 weeks gestational age for the ...

New Zealand has the world's highest rates of serious illness caused by RSV, with 2000 children under five admitted to ...

“We are proud that ABRYSVO has the broadest indication among RSV vaccines, covering older adults, adults 18 and older at heightened risk of severe disease, and pregnant women to help protect ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Pfizer recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at increased risk. Despite this positive development, Pfizer's shares saw a 2% decline ...

Vulnerable Australians aged 50-59 will be able to receive a vaccine for respiratory syncytial virus (RSV).

Infants aged 2 years or younger, pregnant women and adults aged older than 50 years qualify for an FDA-approved RSV vaccine. Abrysvo for pregnant women had the highest administration rate since ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) has issued new separate recommendations supporting expanded use of Pfizer’s respiratory syncytial ...